Abstract
NF-κB is an inducible transcription factor that is controlled by the signal activation cascades. NF-κB controls a number of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis and cell adhesion, thus promoting carcinogenesis and cancer progression. Interestingly, some proteins encoded by oncogenes and oncogenic viruses have been shown to be involved in NF-κB activation pathway. In fact, NF-κB is constitutively activated in some cancer and leukemia cells. These findings have substantiated the old concept of the link between chronic inflammation and carcinogenesis. In this review, we have attempted to overview the possible involvement of NF-κB in cancer and discuss the feasibility of anti-cancer strategy with NF-κB and its signaling cascade as novel molecular targets.
Keywords: NF-κB, signal transduction, IKK, cancer, leukemia, transcription, apoptosis
Current Pharmaceutical Design
Title: NF-κB Signaling and Carcinogenesis
Volume: 13 Issue: 5
Author(s): Takashi Okamoto, Takaomi Sanda and Kaori Asamitsu
Affiliation:
Keywords: NF-κB, signal transduction, IKK, cancer, leukemia, transcription, apoptosis
Abstract: NF-κB is an inducible transcription factor that is controlled by the signal activation cascades. NF-κB controls a number of genes involved in immuno-inflammatory responses, cell cycle progression, inhibition of apoptosis and cell adhesion, thus promoting carcinogenesis and cancer progression. Interestingly, some proteins encoded by oncogenes and oncogenic viruses have been shown to be involved in NF-κB activation pathway. In fact, NF-κB is constitutively activated in some cancer and leukemia cells. These findings have substantiated the old concept of the link between chronic inflammation and carcinogenesis. In this review, we have attempted to overview the possible involvement of NF-κB in cancer and discuss the feasibility of anti-cancer strategy with NF-κB and its signaling cascade as novel molecular targets.
Export Options
About this article
Cite this article as:
Okamoto Takashi, Sanda Takaomi and Asamitsu Kaori, NF-κB Signaling and Carcinogenesis, Current Pharmaceutical Design 2007; 13 (5) . https://dx.doi.org/10.2174/138161207780162944
DOI https://dx.doi.org/10.2174/138161207780162944 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Compounds Derived from Epigallocatechin-3-Gallate (EGCG) as a Novel Approach to the Prevention of Viral Infections
Inflammation & Allergy - Drug Targets (Discontinued) Meet Our Editorial Board Member:
Recent Patents on Anti-Infective Drug Discovery Cancer Therapy By Targeting Hypoxia-Inducible Factor-1
Current Cancer Drug Targets The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature
Mini-Reviews in Medicinal Chemistry Role of Estradiol and Progesterone in HIV Susceptibility and Disease Progression
Mini-Reviews in Medicinal Chemistry Endoglin (CD105): A Target for Anti-angiogenetic Cancer Therapy
Current Drug Targets Gene Therapy to Overcome Drug Resistance in Cancer: Targeting Key Regulators of the Apoptotic Pathway
Current Gene Therapy In Vitro Cytotoxic Activities of Platinum(II) Complex with 1-Methyl-2-(3'- hydroxypropyl)benzimidazole and 2-(3'-Hydroxypropyl)benzimidazolium Hexa- and Tetrachloroplatinate Salts
Letters in Drug Design & Discovery Patent Selections
Recent Patents on Biotechnology Mechanisms of Action of Anesthetics for the Modulation of Perioperative Thrombosis: Evidence for Immune Mechanisms from Basic and Clinical Studies
Current Pharmaceutical Design Modulation of the Cell Cycle and Induction of Apoptosis in Human Cancer Cells by Synthetic Bile Acids
Current Cancer Drug Targets Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Beyond Oncolytic Virotherapy: Replication-Competent Retrovirus Vectors for Selective and Stable Transduction of Tumors
Current Gene Therapy β -Glucans and their Applications in Cancer Therapy: Focus on human studies
Anti-Cancer Agents in Medicinal Chemistry The Association between Tumor-associated Macrophages and Glioblastoma: A Potential Target for Therapy
Current Pharmaceutical Design Ultrasound Assisted Synthesis of 2-Substituted Benzofurans via One-Pot and Sequential Method: Their In Vitro Evaluation
Anti-Cancer Agents in Medicinal Chemistry Commercial Availability of Alpha-Emitting Radionuclides for Medicine
Current Radiopharmaceuticals Glycogen Synthase Kinase-3 Beta; A New Target in Pancreatic Cancer?
Current Cancer Drug Targets Uridine Function in the Central Nervous System
Current Topics in Medicinal Chemistry Let-7a Could Serve as A Biomarker for Chemo-Responsiveness to Docetaxel in Gastric Cancer
Anti-Cancer Agents in Medicinal Chemistry